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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S322Wilcoxon test was used within groups and the Man-Whitney test when
comparing groups. Signiﬁcance level was a p-value of <0.05. All data
given are on the basis of the intention to treat (ITT). To test for a possible
dose-dependency the bodyweight of each patient was plotted against
the different symptom scores, and a correlation test was made on each
of the two groups at the initial level and after 6 and 12 weeks of
treatment.
Results: The two groups were comparable at the initial level regarding
age, sex, bodyweight, consumption of rescue medication and the
severity of OA. Twelveweeks of active treatment resulted in a reduction
inWOMAC pain from 17.79 þ/- 8.80 to 16.57þ/-9.88, p<0.14, whilst the
placebo group showed a decline in pain score from 17.96þ/-7.08 to
14.41 þ/-7.60, p<0.001. Comparing groups yielded a Man-Whitney p-
value of 0.058. No correlation was present between weight and pain
score in either of the two groups on the day of inclusion. After both 6
and 12 weeks of active treatment, there was a signiﬁcant negative
correlation between weight and pain score (p<0.021 and p<0.022,
respectively). The lower the weight the more pronounced the reduction
in pain. No correlation was observed at any time point during placebo.
The ADL score declined from 60.59 þ/-31.33 to 53.91 þ/- 30.59 after 12
weeks of active treatment (p<0.016). Placebo resulted in a decline from
55.71 þ/-25.19 to 43.90 (p<0.001). Comparing groups yielded a Man-
Whitney p-value of 0.098. There was no correlation between weight
and ADL score in either of the two groups on the day of inclusion. Six
and 12 weeks of active treatment, however, resulted in a negative
correlation between weight and ADL score (p<0.019 and p<0.009
respectively). To summarize, the less the weight of the patient the
better the impact from treatment. In the placebo group there was no
signiﬁcant correlation betweenweight and ADL score at any time point.
Similar results for active treatment and placebo were obtained when
testing the secondary effect variable. CRP signiﬁcantly declined as a
result of active treatment. Man-Whitney p-value 0.042.
Conclusions: The present data suggest that patients with osteoarthritis
of the knee or hip can beneﬁt from treatment with the present rose-hip
powder, when given a booster of 5 grams daily for 3 weeks, followed by
2.5 g for the following 9 weeks, with the effect becoming statistically
signiﬁcant in the group of patients of lower weight than 84 kg. This low-
dose also signiﬁcantly reduces CRP.
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EGCG SLOWS POST-TRAUMATIC OA PROGRESSION: IN VIVO
EVIDENCE AND A NOVEL MECHANISM UNDERLYING THE
DOWNREGULATION OF ADAMTS5
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Purpose: There is currently no cure for osteoarthritis (OA), or therapies
which slow or arrest OA progression. Given the nature of OA, decades-
long treatment will likely be required to arrest or slow its progression.
Consequently, there is an urgent need for OA disease-modifying
therapies which in the best case scenario also improve symptoms, and
are safe for clinical use over long periods of time. Nutraceuticals are
derived from food, are generally safe, and provide not only medical or
health beneﬁts, but also exert potential disease- and symptom-mod-
iﬁcation effects in OA. EGCG (epigallocatechin 3-gallate) is a major
bioactive polyphenol present in green tea. Although it remains to be
conﬁrmed by in vivo and clinical studies, recent studies suggest that
EGCG may exert chondroprotective effects in vitro. In this study, we
addressed the question whether EGCG could prevent or slow pro-
gression of post-traumatic OA in vivo. To further dissect the mechanism
underlying EGCG chondroprotection, we: 1) examined the effect of
EGCG in vitro cultured C28/I2 chondrocytes; 2) analyzed the effect of
EGCG on NF-kB subunit p65 and its potential co-factor acetylated H3
(Ac-H3) on ADAMTS5 transactivation using a chromatin immunopre-
cipitation (ChIP) assay.
Methods: EGCG (50 mg/kg) was administered 5 days/week by intra-
peritoneal injection in C57BL/6 mice (male, 5-6 months) subject to
destabilization of the medial meniscus (DMM), starting the same day of
DMM surgery for four weeks (n¼6/group). Limbs from DMMmice were
then sacriﬁced and OA severity was evaluated by Safranin O staining
and OARSI score. Immunohistochemical analysis was performed to
detect cleaved aggrecan (NITEGE), denatured type II collagen (Col2 3/
4M), and expression of MMP-13 and ADAMTS5. C28/I2 chondrocyteswere cultured to semi-conﬂuence and were treated with EGCG for 6
hours in the presence and absence of IL-1b and were harvested for RT-
qPCR. For ChIP assay, cell lysates were immunopreciptated (IP) with
antibodies speciﬁc to p65, acetylated H3, or control IgG. Amounts of
speciﬁc DNA fragments were quantiﬁed by real-time PCR using primers
speciﬁc for p65 binding sites in the ADAMTS5 promoter region and
normalized against the genomic DNA preparation from the same cells
(input).
Results: In vivo: Four weeks after EGCG treatment, the cartilage in the
DMM limb in the EGCG-treated mice exhibited signiﬁcantly less
Safranin O loss and cartilage ﬁbrillation, and lower OARSI score com-
pared to vehicle-treated controls (Fig 1A, B). Administration of EGCG
protected cartilage integrity by reducing degradation of aggrecan and
type II collagen, and suppressed expression of MMP-13 and ADAMTS5
(Fig 1C). In vitro: EGCG suppresses expression of ADAMTS5 in chon-
drocytes in the presence of IL-1b (Fig 2A). ChIP assay revealed EGCG
reduces p65 binding and histone H3 on the p65 binding sites of the
ADAMTS5 promoter as shown by reduced PCR-ampliﬁed DNA products
(Fig 2B). This data suggests EGCG suppresses ADAMTS5 expression by,
at least in part, interrupting p65 binding to the promoter of ADAMTS5
through a mechanism that involves Ac-H3.
Conclusions: We demonstrated efﬁcacy of EGCG in slowing OA pro-
gression by preserving cartilage integrity and suppressing key cartilage
degradative enzymes. Our ﬁndings provide a rational basis for
advancing EGCG-based treatments toward future clinical trials and
treatment. Furthermore, the molecular mechanisms uncovered could
provide novel molecular targets for the treatment of OA.
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SULFORAPHANE REPRESSES MATRIX-DEGRADING PROTEASES AND
PROTECTS CARTILAGE FROM DESTRUCTION IN VITRO AND IN VIVO
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Purpose: Nutrition impacts directly on ageing and obesity, both of
which are major risk factors for osteoarthritis. Sulforaphane (SFN) is an
isothiocyanate derived from brassicas, particularly broccoli, and has
been reported to regulate signalling pathways relevant to chronic dis-
eases. Our study investigated whether sulforaphane can abrogate car-
tilage destruction in laboratory models of osteoarthritis and examined
mechanism of action in chondrocytes.
Methods: The impact of SFN treatment on gene expression, signalling
through transcription factors nuclear factor (erythroid-derived 2)-like 2
(Nrf2) and nuclear factor kappaB (NFkB), and histone acetylation were
examined in chondrocytes. The intracellular concentrations of SFN and
SFN metabolites were quantiﬁed in chondrocytes and used to inform
transcription factor binding assays. The bovine nasal cartilage explant
model (BNC) and destabilisation of medial meniscus (DMM) murine
model of osteoarthritis were used to study chondroprotection by SFN.
Results: SFN inhibited cytokine-induced metalloproteinase expression
in primary human articular chondrocytes (HACs) and in ﬁbroblast-like
synovial cells (FLS). SFN can act independently of the Nrf2 transcription
factor and histone deacetylase activity in HACs, but does mediate pro-
longed activation of Jun kinase (JNK) and p38 MAP kinase. SFN
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in HACs with attenuation of expression of several NF-kB dependent
genes. SFN abrogates cytokine-induced destruction of bovine nasal
cartilage at the level of both proteoglycan and collagen breakdown
(10mM compared to cytokines alone). It also decreases arthritis score in
the DMM murine model of osteoarthritis (3mmol daily dose SFN in diet
versus control chow).
Conclusions: SFN, at levels which can be obtained through a broccoli-
rich diet, inhibits the expression of key metalloproteinases implicated
in osteoarthritis independently of Nrf2 and blocks inﬂammation at the
level of NF-kB to protect against cartilage destruction in vitro and in
vivo. Ongoing studies in man will ascertain the potential of this com-
pound in human osteoarthritis.
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IDENTIFYING DIET-DERIVED CHONDROPROTECTIVE COMPOUNDS IN
OSTEOARTHRITIS
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Purpose: Current pharmacological intervention for osteoarthritis (OA)
is focused on inﬂammation and pain relief rather than addressing the
degradation of articular cartilage. Such treatments typically have a
single mode of action in a multifactorial disease. Compounds present in
the habitual diet are as an attractive alternative, since foods typically
contain multiple bioactive compounds that can interact with multiple
cellular pathways. The purpose of this study was to identify novel
chondroprotective compounds from the habitual diet.
Methods: Since matrix metalloproteinase-13 (MMP-13) is considered a
key collagen-degrading enzyme, inhibition of MMP13 expression,
measured by qRT-PCR, was used as a surrogate marker of cartilage
degradation. Ninety-six diet derived compounds were selected from a
list of compounds based on (i) the edibility of the source; (ii) how
commonly it was consumed; (iii) whether the compound had pre-
viously been studied in chondrocytes. Compounds (at 10 mM) were
screened in triplicate against basal expression and inhibition of inter-
leukin-1 (IL-1)-induced expression of MMP13 in SW1353 chon-
drosarcoma cells and the C28/I2 immortalised human chondrocyte cell
line. The lead compounds from these screens were then assayed in
three isolates of primary human articular chondrocytes for their impact
on expression of MMP13, MMP1, ADAMTS4 and ADAMTS5. Compound
toxicity was measured using lactate dehydrogenase release and FACS.
Results: All compounds tested were non-toxic at 10mM. Six compounds
signiﬁcantly reduced IL-1-induced MMP13 expression in SW1353 cells,
whilst eleven compounds signiﬁcantly reduced IL-1-induced MMP13
expression in C28/I2 cells (p<0.05 - p<0.0001). Of these compounds
assayed in primary human articular chondrocytes, ﬁve compounds
signiﬁcantly inhibited both IL-1-induced MMP1 andMMP13 expression
(apigenin, aloe emodin, emodin, luteolin and isoliquiritigenin). Apige-
nin signiﬁcantly inhibited IL-1-induced ADAMTS5 and aloe emodin
signiﬁcantly inhibited IL-1-induced ADAMTS4 (p<0.05 - p<0.01). Api-
genin, aloe emodin and isoliquiritigenin showed dose-dependency
across the 2.5 - 40mM range.
Conclusions: This screen has identiﬁed a number of target compounds
which have the potential to be chondroprotective. Apigenin is a ﬂavone
found in various plants including celery and swede; aloe emodin is a
hydroxyanthraquinone found in aloe vera; isoliquiritigenin is a chal-
cone from licorice. These compounds will now be taken forwards for
further analyses.
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THE IN VITRO EFFECTS OF PROCYANIDINS AND HYDROXYTYROSOL-
CONTAINING GRAPE AND OLIVE EXTRACT MIX ON THE
INFLAMMATION-ASSOCIATED OSTEOARTHRITIS PROCESSES
E. Mevel y,z, C. Merceron y,x, M. Masson y,x, N. Urban z, L. Beck y,x,
J. Guicheux y,k. y INSERM UMR 791, Nantes, France; zUnion Grap’Sud,
Cruviers-Lascours, France; xUniversite de Nantes, UFR Odontologie,
Nantes, France; kCHU Nantes, PHU 4 OTONN, Nantes, France
Purpose: Osteoarthritis (OA) is a major health concern that affects a
growing part of our aging population associated with strong socio-
economic burdens. To date, there is no curative treatment for OA.
Pharmaceutical drugs alleviate inﬂammation and pain but nonesucceeds to slow down, stop or reverse the progression of the cartilage
degradation and other adverse tissue injuries related to the pathology.
In the last decades, many studies tried to demonstrate the effectiveness
of herbal medicines to treat OAwithout the side effects associated with
pharmacological treatments. This growing interest has led to the
emerging concept of nutraceuticals. Among these nutraceuticals, phe-
nolic phytochemicals compounds like procyanidins and hydroxytyrosol
are now well acknowledged for their potent antioxidant and anti-
inﬂammatory effects. There is, however, no scientiﬁc evidence to show
the efﬁcacy and safety of these compounds for OA prevention. In this
study, we examined the effects of a grape and olive extract mix (OPCO)
containing a high concentration of procyanidins and hydroxytyrosol on
the in vitro and ex vivo inﬂammation-associated OA events.
Methods: OPCO (Grapsud, France) was characterized for its procyani-
dins and hydroxytyrosol contents by vanillin method and HPLC. Human
articular choncrocytes (HAC), rabbit articular chondrocytes (RAC) and
cartilage explants were harvested from tibial plateau and femoral
condyles of 7 weeks-old New Zealand white rabbits and human
cadavers. Cell viability was evaluated with a Methyl tetrazolium salt
(MTS) assay. To mimick the inﬂammatory conditions of OA, cells were
treated with IL-1b (1ng/mL) for 24 and 48H and culture media were
then collected for nitric oxide (NO) and prostaglandin E2 (PGE2)
measurements. The NO production was investigated by the Griess
method, and PGE2 production was determined by Enzyme-linked
immunosorbent assay (ELISA). The nuclear translocation of NF-kB
(subunit p65) in HAC treated with IL-1b in the presence of OPCO was
investigated by immunoﬂuorescence using a speciﬁc antibody.
Results: Our results showed that OPCO contained 30% and 6.4% of
procyanidin and hydroxytyrosol, respectively. MTS assay indicated that
OPCO did not affect HAC and RAC viability. Our results also showed that
IL-1b treatment induced a 3.5, 8 and 9.5 fold increase in the NO pro-
duction in RAC, HAC and human explants, respectively. In addition, IL-
1b treatment triggered a 7-, 33- and 1300-fold increase in PGE2 pro-
duction in RAC, HAC and human explants, respectively. Interestingly, a
24H pretreatment of RAC, HAC and human explants with OPCO induced
a signiﬁcant reduction in the IL-1b-induced production of NO by 32%,
54%, and 60%, respectively. The IL-1b-dependent synthesis of PGE2 in
RAC, HAC and explants was also reduced by about 75%, 97%, and 97%,
respectively. Finally, whereas IL-1b was found to induce the nuclear
translocation of p65 NF-kB, OPCO was shown to inhibit the IL-1b-
induced nuclear translocation of p65 NF-kB in HAC.
Conclusions: In this study we have showed that a grape and olive
extract, containing high amount of procyanidin and hydroxytyrosol,
may carry out potent anti-inﬂammatory activities through the inhib-
ition of IL-1b-driven NO and PGE2 production. In addition, our results
strongly suggest that the anti-inﬂammatory activity of OPCO is likely to
be mediated at least through the inhibition of p65 NF-kB pathway.
Further in vivo experiments in adapted animal models of OA are now
under investigation to determine whether grape and olive extracts may
be promising nutraceuticals for the prevention of inﬂammation-asso-
ciated OA symptoms.
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BENEFICIAL EFFECT OF 3-HYDROXYTYROSOL ON CHONDROCYTES
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Purpose: A major opportunity is represented by the search for food-
derived molecules able to interfere with the processes involved in the
pathogenesis or progression of chronic degenerative- and age-related
diseases, such as osteoarthritis (OA). Recent ﬁndings attributed a
potential role to autophagy in the regulation of the cellular response to
several stress stimuli. Although its role is context- and tissue-depend-
ent and still unclear, autophagy has been observed to decrease during
aging and several age-related diseases, including OA. Here we address
the question whether 3-hydroxytyrosol (HT) pre-treatment of chon-
drocyte cultures is able to reduce cell death, terminal chondrocyte
differentiation and matrix degradation induced by oxidative stress. This
natural compound is one of the major polyphenols present in olive oil
